Welcome to our dedicated page for Orchestra BioMed Holdings news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings stock.
Orchestra BioMed Holdings, Inc. develops biomedical technologies through strategic partnerships with global medical device companies. Its recurring news centers on two late-stage cardiovascular programs: Atrioventricular Interval Modulation Therapy, or AVIM Therapy, for hypertension, and Virtue Sirolimus AngioInfusion Balloon, or Virtue SAB, for atherosclerotic artery disease.
Company updates commonly cover pivotal trial activity, clinical and mechanistic data presentations, FDA Breakthrough Device Designation matters for AVIM Therapy, strategic financing from partners, revenue participation arrangements, and equity-based employee inducement grants. Financial-result releases also discuss cash resources, non-recurring revenue tied to program agreements, and execution of the company's partnership-driven development model.
Orchestra BioMed (OBIO) granted stock options for an aggregate 133,000 common shares to seven newly hired employees on September 1, 2026. The options were issued under the company’s 2025 New Hire Inducement Plan as a material inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). Each grant will vest over a four-year period. Orchestra BioMed states that it is disclosing these awards to comply with Nasdaq’s inducement grant disclosure requirements.
Orchestra BioMed (Nasdaq: OBIO) announced that Chairman and CEO David Hochman is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:00 a.m. ET in New Hope, Pennsylvania. The company also plans to host one-on-one investor meetings that day.
Orchestra BioMed (Nasdaq: OBIO) announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026 at 1:30 p.m. ET. The company will also hold one-on-one investor meetings on September 9 and 10. A live webcast and replay will be available via Orchestra BioMed’s Investor Relations website.
Orchestra BioMed (Nasdaq: OBIO) reported second quarter 2026 results and updates on its pivotal cardiovascular programs. The BACKBEAT global pivotal trial of AVIM Therapy, conducted with Medtronic, is on track to reach 284 evaluable randomized patients by the end of Q3 2026, with primary endpoint data presentation targeted for Q2 2027. The Virtue SAB pivotal trial for coronary in-stent restenosis continues to progress with additional site activations and patient enrollment, and AVIM Therapy received a second FDA Breakthrough Device Designation.
According to Orchestra BioMed, Q2 2026 cash, cash equivalents and marketable securities totaled $110.0 million, including $35 million in new strategic capital from Medtronic and Ligand, providing projected runway into Q4 2027. Q2 revenue was $0.1 million, research and development expenses were $16.6 million (up 20% year over year), selling, general and administrative expenses were $5.8 million (down 7%), and net loss attributable to common stockholders was $24.1 million, or ($0.38) per share. The company was added to the Russell 3000 and Russell 2000 indexes and plans an R&D Day on November 12, 2026, in New York City.
Orchestra BioMed (Nasdaq: OBIO) announced that it joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, effective after the U.S. market close on June 26, 2026.
Membership, based on FTSE Russell’s market-cap rankings and style attributes, lasts until the next semi-annual reconstitution and brings automatic inclusion in related growth and value indexes.
Russell indexes are widely used benchmarks, with approximately $12.2 trillion in assets tied to their U.S. indexes.
Orchestra BioMed (Nasdaq: OBIO) announced that its Board’s Compensation Committee granted stock options to purchase an aggregate of 85,500 common shares to five newly hired employees on June 1, 2026.
The options, issued under the 2025 New Hire Inducement Plan, will vest over four years and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Orchestra BioMed (Nasdaq: OBIO) announced participation in the Jefferies Global Healthcare Conference. Chairman and CEO David Hochman will join a fireside chat with Jefferies Managing Director Matt Taylor at 9:55 a.m. ET on Thursday, June 4, 2026.
He will also host one-on-one investor meetings on June 3 and 4. The fireside chat will be available via live webcast on the company’s Investor Relations website, open to investors and other interested parties.
Orchestra BioMed (Nasdaq: OBIO) reported Q1 2026 results and clinical progress. Cash, cash equivalents and marketable securities were $94.4 million on March 31, 2026, with a projected cash runway into Q4 2027. Q1 revenue was $0.1 million and net loss attributable to common stockholders was $20.7 million ($0.33/share).
The Company targets completion of BACKBEAT Trial enrollment by Q3 2026, aims for a late-breaking data presentation in Q2 2027, and received a second FDA Breakthrough Device Designation for AVIM Therapy. It also secured $35 million in strategic capital from Medtronic and Ligand and continues to advance the Virtue Trial.
Orchestra BioMed (Nasdaq: OBIO) updated the clinical and regulatory timeline for the global pivotal BACKBEAT Trial of AVIM Therapy in pacemaker-indicated patients with uncontrolled hypertension. Enrollment completion is targeted by the end of Q3 2026, with primary endpoint data planned for presentation in Q2 2027.
The FDA approved a reduction in sample size to 284 evaluable randomized subjects (total enrollment target 316) under the Breakthrough Devices program, while maintaining >90% power to detect at least a 5 mmHg difference in 24-hour ambulatory systolic blood pressure at 3 months. Assuming primary safety and efficacy endpoints are met, Medtronic intends to submit an AVIM Therapy-related marketing application for FDA approval after data analyses and then pursue global approvals.
Orchestra BioMed (Nasdaq: OBIO) received a $15 million tranche from Ligand under a previously announced royalty purchase agreement, completing a scheduled payment and bringing Ligand capital to $40 million to date. The financing grants Ligand a tiered royalty interest in Orchestra BioMed’s future revenue.
Proceeds will fund ongoing randomized pivotal trials for AVIM Therapy and Virtue SAB. Together with a separate $20 million Medtronic investment, Orchestra reported $35 million in fresh strategic capital received on May 1, 2026.